A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus
cancer.
Patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder,
urachal will be enrolled this study.
Modified version of FOLFIRINOX(Oxaliplatin 85 mg/m 2, Leucovorin 400mg/m2 , irinotecan
150mg/m2 and 5-FU 2400mg/m2) with prophylactic pegateograstim will be continued till
progression, unacceptable toxicity, or till 12 cycles (24 weeks). Study drugs can be
administered after 12 cycles to the subjects with benefit from study medication.
Response evaluation will be done every 6 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Boryung Pharmaceutical Co., Ltd Green Cross Corporation